Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
2,3,4
- 2,3,4
“This year’s abstracts showcase the breadth of the data we will be presenting at DDW, reaffirming Phathom’s continued commitment to helping improve the lives of people affected by acid-related gastrointestinal disorders,” said Eckhard Leifke, M.D., Chief Medical Officer at Phathom. - “Notably, we are excited to unveil novel findings highlighted in three posters and an oral presentation during the conference, including the first time data from our Phase 3 study of the investigational use of VOQUEZNA in Non-Erosive GERD will be presented during a medical congress.
- In addition to these three poster sessions and one oral presentation, Phathom will sponsor a product theater highlighting VOQUEZNA as an approved treatment for Erosive Esophagitis, also referred to as Erosive GERD, and will also have a presence on the exhibit floor at booth #911 throughout the conference.
- A high-level schedule of Phathom activities at DDW 2024 can be found below: